ALPK3 Cardiomyopathy: Integrative Review With Systematic Variant Curation, Mechanisms, and Translation
Circulation: Genomic and Precision Medicine · 2025
DOI: 10.1161/circgen.125.005368 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Circulation: Genomic and Precision Medicine, 2025. Verfasst von Chien-Wei Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego (C.-W.C., L.W., Z.C., J.B., J.C.). Hauptthemen laut MEDLINE: Cardiomyopathies, Cardiomyopathy, Hypertrophic. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Pathogenic variants in ALPK3 (α-protein kinase 3), an atypical α‑kinase acting as a sarcomeric M-band scaffold, cause cardiomyopathy with severity linked to zygosity. We present a comprehensive review with systematic curation of peer-reviewed clinical and experimental reports through June 9, 2025, encompassing 156 patient-level variants and all published preclinical models. Biallelic loss-of-function variants lead to severe, often lethal cardiomyopathy with prenatal or early onset presentation and extracardiac involvement. Heterozygous protein-truncating variants, defined as nonsense or frameshift (resulting from insertion/deletion events or splicing mutations), explain ≈1% to 4% of adult hypertrophic cardiomyopathy, often with apical/septal hypertrophy, right ventricular involvement, fibrosis, and risk of progression. ALPK3 lacks catalytic activity and maintains sarcomeric proteostasis by scaffolding MYOMs (myomesins), MuRF (muscle ring-finger protein) E3 ligases, and SQSTM1 (sequestosome-1)/p62. Loss of this scaffolding function displaces MYOMs, drives thick‑filament protein aggregation, and precipitates severe contractile dysfunction in human induced pluripotent stem cell–derived cardiomyocytes and multiple mouse models. Therapeutic proof‑of‑concept has now been achieved on 2 fronts: (1) pharmacological correction of sarcomeric hypercontractility with the myosin inhibitor mavacamten and (2) durable phenotypic rescue in global knockout mice using an adeno-associated virus–delivered miniALPK3 gene‑replacement construct. Together, these data position ALPK3 cardiomyopathy as a compelling target for precision medicine. Early genetic diagnosis, genotype-tailored surveillance, and focused development of gene-replacement or editing strategies, potentially combined with modulators of the ALPK3-MuRF proteostatic axis, offer a realistic path to disease-modifying therapy for this once enigmatic condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego (C.-W.C., L.W., Z.C., J.B., J.C.).
- Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan (C.-W.C.).
ORCID-Profile: Chien-Wei Chang, Li Wang, Zeyu Chen, Julius Bogomolovas, Ju Chen
Förderung
- NHLBI NIH HHS
Zitieren
APA
Chang, C. W., Wang, L., Chen, Z., Bogomolovas, J., & Chen, J. (2025). ALPK3 Cardiomyopathy: Integrative Review With Systematic Variant Curation, Mechanisms, and Translation. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.125.005368
Vancouver
Chang CW, Wang L, Chen Z, Bogomolovas J, Chen J. ALPK3 Cardiomyopathy: Integrative Review With Systematic Variant Curation, Mechanisms, and Translation. Circulation: Genomic and Precision Medicine. 2025. doi:10.1161/circgen.125.005368
BibTeX
@article{Chang2025,
author = {Chang, Chien-Wei and Wang, Li and Chen, Zeyu and Bogomolovas, Julius and Chen, Ju},
title = {ALPK3 Cardiomyopathy: Integrative Review With Systematic Variant Curation, Mechanisms, and Translation},
journal = {Circulation: Genomic and Precision Medicine},
year = {2025},
doi = {10.1161/circgen.125.005368}
}
EUVIMED